Parametric Portfolio Associates LLC Has $1.16 Million Stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

Share on StockTwits

Parametric Portfolio Associates LLC lifted its position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 13.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,379 shares of the company’s stock after acquiring an additional 3,116 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Biohaven Pharmaceutical were worth $1,155,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Aperio Group LLC acquired a new stake in shares of Biohaven Pharmaceutical during the 2nd quarter valued at $71,000. Glen Harbor Capital Management LLC raised its position in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after purchasing an additional 1,088 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Biohaven Pharmaceutical by 94.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock worth $99,000 after purchasing an additional 1,097 shares during the last quarter. Tyers Asset Management LLC raised its position in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Tyers Asset Management LLC now owns 2,398 shares of the company’s stock worth $105,000 after purchasing an additional 1,496 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Biohaven Pharmaceutical during the 2nd quarter worth $109,000. 90.90% of the stock is currently owned by institutional investors.

BHVN stock opened at $43.01 on Friday. The stock has a 50-day moving average price of $42.37 and a 200-day moving average price of $49.16. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $29.17 and a 1-year high of $67.86. The firm has a market cap of $2.17 billion, a PE ratio of -6.99 and a beta of 0.32.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.09) by ($0.26). On average, equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -7.51 earnings per share for the current year.

Several research analysts recently issued reports on the company. Canaccord Genuity set a $80.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 26th. William Blair reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 17th. Morgan Stanley set a $50.00 target price on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research report on Friday, August 9th. ValuEngine lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, June 19th. Finally, Oppenheimer set a $67.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Biohaven Pharmaceutical has an average rating of “Buy” and an average price target of $69.27.

In other news, Director Eric Aguiar sold 10,000 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gregory Bailey acquired 5,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $37.65 per share, with a total value of $188,250.00. Following the completion of the transaction, the director now owns 2,587,601 shares in the company, valued at approximately $97,423,177.65. The disclosure for this purchase can be found here. Company insiders own 23.90% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.